VERV (Verve Therapeutics) Insider Ownership : 1.29 % (As of Apr. 29, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Verve Therapeutics's insider ownership is 1.29%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Verve Therapeutics's Institutional Ownership is 88.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Verve Therapeutics's Float Percentage Of Total Shares Outstanding is 84.20%.

Verve Therapeutics Insider Ownership Historical Data

The historical data trend for Verve Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics Insider Ownership Chart

Verve Therapeutics Historical Data

The historical data trend for Verve Therapeutics can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Insider Ownership	1.39	1.39	1.38	1.38	1.38	1.38	1.35	1.35	1.29	1.29

Verve Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Verve Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215

Website

https://www.vervetx.com

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Executives

Joan Nickerson	officer: Chief Administrative Officer	C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Sekar Kathiresan	director, 10 percent owner, officer: Chief Executive Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Andrew D. Ashe	officer: See Remarks	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Allison Dorval	officer: Chief Financial Officer	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Krishna Yeshwant	director, 10 percent owner	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Fred T. Fiedorek	officer: Chief Medical Officer	55 BALDWIN LANE, PRINCETON NJ 08540
Andrew Bellinger	officer: Chief Scientific Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	other: Member of 10% Group	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Lonnel Coats	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman	director, 10 percent owner	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Logos Global Management Lp	10 percent owner	1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129